Sophia GeneticsSOPH +0.97%72 Current Ratio is 2.06 as of Mar. 2026, which is 53% below its 10-year median of 4.38. GuruFocus rates SOPH with a GF Score™ of 72/100 and a GF Value™ of $5.03 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 680 Healthcare Providers & Services companies, Sophia Genetics ranks better than 66.03% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Sophia Genetics's current ratio for the quarter that ended in Mar. 2026 was 2.06.
Sophia Genetics has a current ratio of 2.06. It generally indicates good short-term financial strength.
The historical rank and industry rank for Sophia Genetics's Current Ratio or its related term are showing as below:
SOPH'
s Current Ratio Range Over the Past 10 Years
Min: 1.75 Med: 4.38 Max: 10.84
Current: 2.06
During the past 8 years, Sophia Genetics's highest Current Ratio was 10.84. The lowest was 1.75. And the median was 4.38.
SOPH's Current Ratio is ranked better than 66.03% of 680
companies
in the Healthcare Providers & Services industry
Industry Median: 1.47
vs SOPH: 2.06
Sophia Genetics (NAS:SOPH) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Sophia Genetics Current Ratio Related Terms
Sophia Genetics Current Ratio Historical Data
* Premium members only.
The historical data trend for Sophia Genetics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Sophia Genetics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sophia Genetics Current Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sophia Genetics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Sophia Genetics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sophia Genetics (SOPH) has a Current Ratio of 2.06 as of Mar. 2026. This is 53% below median its historical median of 4.38. Over the past decade, Sophia Genetics' Current Ratio has ranged from 1.75 to 10.84. According to the industry distribution chart, Sophia Genetics ranks #231 out of 680 companies in the Healthcare Providers & Services industry, placing it in the top 34%.
Is Sophia Genetics' Current Ratio too high?
Sophia Genetics' current Current Ratio of 2.06 is 53% below median its 10-year median of 4.38. Over the past 10 years, this metric has ranged from a low of 1.75 to a high of 10.84. The Healthcare Providers & Services industry median Current Ratio is 1.47. Sophia Genetics' value of 2.06 is 40.1% above this industry median. Based on the distribution chart, Sophia Genetics ranks #231 out of 680 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Sophia Genetics has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sophia Genetics' Current Ratio compare to SLP and TBRG?
According to the Healthcare Providers & Services industry distribution chart, Sophia Genetics ranks #231 out of 680 companies for Current Ratio. This puts Sophia Genetics in the upper half of its industry. The industry median Current Ratio is 1.47. Sophia Genetics' value of 2.06 is 40.1% above this benchmark. Historically, Sophia Genetics' own Current Ratio has ranged from 1.75 to 10.84 over the past decade. While the company's 10-year median is 4.38 vs. the industry median of 1.47, Sophia Genetics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Healthcare Providers & Services company?
The median Current Ratio among Healthcare Providers & Services companies is 1.47, based on 680 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sophia Genetics's current Current Ratio of 2.06 is 40.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Current Ratio is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sophia Genetics's current Current Ratio is 2.06, which is 53% below median its own 10-year median of 4.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sophia Genetics stock overvalued right now?
Based on GuruFocus' analysis, Sophia Genetics (SOPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.03, compared to a current price of $5.75 — trading 14.3% above its estimated fair value. The current Current Ratio is 2.06, which is 53% below median its 10-year median of 4.38 and 40.1% above the Healthcare Providers & Services industry median of 1.47. Sophia Genetics' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Sophia Genetics (SOPH), the current Current Ratio is 2.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sophia Genetics (SOPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued.
The current stock price of $5.75 is trading 14.3% above its estimated GF Value™ of $5.03.
GuruFocus considers Sophia Genetics to be Modestly Overvalued.
Key valuation signals for SOPH:
Current Ratio: 2.06 (53% below median its 10-year median of 4.38)
GF Value™: $5.03 vs. price of $5.75 (14.3% above fair value)
Industry Position: 40.1% above the Healthcare Providers & Services median (#231 of 680)
No single metric tells the full story. See the SOPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
72GF Score
Get the complete analysis for SOPH
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SOPH has been successfully added to your 
